|
 |
 Home > Available Issues |
|
|
 Original Articles |
| Roxithromycin in the Treatment of Lower Respiratory Tract Infections |
| Woo Joo Kim, Yoon Sang Choi, Sang Won Shin, Min Ja Kim, Seung Chull Park |
| Department of Internal Medicine, College of Medicine, Korea University, Seoul, Korea |
Vol.23 Num.1 (p39~43)
|
|
|
Roxithromycin is a newer macrolide which possesses a wide spectrum of antimicrobial activity, favorable pharmacokinetics and good tolerance. This study was designed to evaluate the clinical efficacy, safety and tolerance of roxithromycin in the treatment of lower respiratory tract infections (LRTI).
A total number of 20 patients (9 males and 11 females) were included in prospective non-controlled study. They presented LRTI: acute suppurative bronchitis (4 cases) and acute pneumonia (16 cases). Roxithromycin was given orally at the dose of 150mg twice daily for 7 to 14 days. Successful clinical response was observed in 19/20 patients (95%), including all 12 patients (100%) with acute bronchitis and 15/16 patients (94%) with pneumonia. Isolated pathogens from sputum culture included S. pneumoniae(4), S. marcescens (1), and A. calcoaceticus (1). All pathogens except A. calcoaceticus were eradicated. Satisfactory therapeutic responses were observed in all 5 patients with serologically confirmed Mycoplasma pneumoniae infection. The tolerance to roxithromycin was good in 19 out of 20 patients (95%). One patient experienced mild epigastric discomfort and showed transient elevation of transaminase levels.
In conclusion, roxithromycin administered proved to be an effective, safe and convenient antibiotic in the treatment of LRTI.
|
|
|
Keywords : |
|
|
|
|
|
|
|
|
